iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: Yahoo! Finance
GALAXIES Lung-201 - Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy - GSK to provide update on GALAXIES program at upcoming investor event in June - RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close - Pro forma cash and investment balance of $715 million as of March 31, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. “After reviewing headline data for an interim assessment of GALAXIES Lung-201, we are thrilled to announce tha
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- iTeos Therapeutics Announces $120 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- iTeos Therapeutics Announces $120 Million Registered Direct OfferingGlobeNewswire
- iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
ITOS
Earnings
- 5/10/24 - Miss
ITOS
Sec Filings
- 5/15/24 - Form SC
- 5/14/24 - Form 4
- 5/14/24 - Form SC
- ITOS's page on the SEC website